Table of Contents
Overview
New York, NY – July 15, 2025 : The Catheter Related Bloodstream Infection Market is projected to grow from US$ 1.5 billion in 2023 to US$ 2.5 billion by 2033. This reflects a compound annual growth rate (CAGR) of 5.2% between 2024 and 2033. One of the key drivers behind this growth is the increasing number of CRBSI cases. These infections are a major concern in healthcare facilities, especially for patients who require long-term catheterization. Rising infection rates are pushing demand for improved prevention and treatment solutions.
CRBSIs are commonly seen in patients undergoing hemodialysis, those in intensive care units (ICUs), and individuals on long-term treatments using central venous catheters (CVCs). These infections can lead to life-threatening complications and extend hospital stays. The growing use of CVCs, particularly among elderly and chronically ill patients, is driving market expansion. Hospitals and clinics are actively seeking safer alternatives and better protocols to reduce infection risks associated with catheter usage.
In December 2022, CorMedix conducted a major study using both clinical and claims data from kidney failure patients receiving hemodialysis through CVCs. The study aimed to create new therapeutic options for preventing and managing CRBSIs. Its findings highlighted the clinical urgency and economic burden of treating these infections. The data supports the development of innovative solutions that can improve patient safety. Such research efforts are expected to boost investments and drive innovation across the global CRBSI market.
With the increasing number of patients requiring central lines, the need for infection control has grown. This creates strong market demand for advanced catheter designs, antimicrobial coatings, and improved maintenance techniques. Hospitals are focusing more on preventing healthcare-associated infections (HAIs), which supports the adoption of CRBSI prevention tools. In addition, regulatory bodies and health organizations are encouraging best practices and technology upgrades. These efforts are reshaping market dynamics and creating opportunities for new product introductions.
Recent trends show a strong shift toward preventive strategies. Antiseptic locks, catheter surface modifications, and other innovations are gaining popularity among healthcare providers. These technologies help reduce microbial colonization and minimize infection risk. At the same time, companies are increasing investments in research and development for infection control. With healthcare systems striving for better outcomes and lower costs, the catheter-related bloodstream infection market is expected to grow steadily. Continued innovation will remain key to addressing the ongoing challenge of CRBSIs.
Key Takeaways
- In 2023, the catheter-related bloodstream infection market earned US$ 1.5 billion and is set to hit US$ 2.5 billion by 2033.
- The market is growing steadily at a compound annual growth rate (CAGR) of 5.2% over the forecast period from 2024 to 2033.
- Among drug classes, echinocandin led the pack in 2023, capturing the highest market share at 45.5% due to its antifungal effectiveness.
- When it comes to administration methods, oral drugs were preferred, accounting for 55.8% of the total market share in 2023.
- Fungal infections were the most treated indication in this space, contributing 50.1% of the market revenue, outperforming bacterial and viral infections.
- Hospital pharmacies dominated distribution channels, holding a 50.6% market share thanks to their central role in managing serious bloodstream infections.
- North America emerged as the top regional market, securing 37.5% of the total market share in 2023 due to advanced healthcare infrastructure.
Regional Analysis
North America is leading the Catheter Related Bloodstream Infection Market
North America holds the largest share in the catheter-related bloodstream infection (CRBSI) market, accounting for 37.5% of total revenue. This is due to advanced infection prevention technologies and rising awareness of healthcare-associated infections. CRBSIs often affect patients using central venous catheters for treatments like dialysis or IV medication. A notable 2023 study, the LOCK IT-100 trial by the University of California, showed that a taurolidine/heparin mix significantly reduced CRBSI rates compared to heparin alone, improving patient outcomes in critical care.
The North American market also benefits from high healthcare spending and strong investments in infection control measures. Hospitals in the region are adopting advanced protocols and catheter technologies to minimize infection risks. With an ongoing focus on patient safety and technology-driven solutions, the demand for CRBSI prevention products is set to grow. These trends position North America as a dominant player, and continued market expansion is expected as healthcare providers aim to lower infection-related complications.
Asia Pacific Region to Witness Highest Growth Rate
The catheter-related bloodstream infection market in the Asia Pacific is projected to grow at the fastest CAGR during the forecast period. Key growth drivers include rising healthcare investments and stronger infection prevention efforts. Countries like India and China are modernizing their healthcare systems rapidly. As per India Brand Equity Foundation (IBEF), India’s healthcare sector is growing at a 22% CAGR, aiming to reach US$ 372 billion by 2022, up from US$ 110 billion in 2016. This growth is expected to increase demand for infection control technologies.
As more patients receive central venous catheters, the risk of CRBSIs will also rise. This will boost demand for advanced diagnostic and preventive tools. Growing awareness about infection prevention and better access to healthcare are also contributing to market expansion. The region’s focus on innovation and medical technology is expected to drive the adoption of products that reduce CRBSI cases. As a result, the Asia Pacific market is poised for strong and sustained growth in the coming years.
Segmentation Analysis
Drug Class Analysis
In 2023, the echinocandin segment dominated the market with a 45.5% share. This was due to its growing effectiveness against fungal infections linked to catheter use. Echinocandins have broad-spectrum activity, especially against Candida species, making them a preferred treatment. Their favorable safety profile and clinical outcomes also boost their demand. The rising number of immunocompromised patients, such as those undergoing chemotherapy or transplants, supports this trend. As hospitals face more catheter-related infections, echinocandins are increasingly used as a first-line therapy in both hospitals and clinics.
Route of Administration Analysis
The oral route held a significant 55.8% market share due to growing demand for patient convenience. Oral drugs are easy to administer, especially in outpatient or homecare settings. Many healthcare providers now prefer oral antifungals and antibiotics for mild or moderate infections. Advancements in formulation technology have improved the absorption of oral medications, making them more effective. This trend supports non-invasive treatment options. As home-based care increases, oral drug usage is likely to rise, offering patients flexibility while maintaining therapeutic effectiveness.
Indication Analysis
Fungal infections led the indication segment with a 50.1% share in 2023. The increase in long-term catheter use has raised the risk of fungal infections, especially among vulnerable groups like cancer or HIV/AIDS patients. Candida infections are particularly common in catheter-related bloodstream infections. The limited availability of treatments for resistant fungal strains drives demand for targeted antifungal therapies. As awareness of these infections grows, healthcare providers are prioritizing their management. This trend will likely push further innovation and demand for effective antifungal drugs tailored for catheter-associated conditions.
Distribution Channel Analysis
Hospital pharmacies accounted for 50.6% of the market in 2023. This is due to their critical role in managing bloodstream infections that require specialized care. Hospitals often deal with complex cases involving intravenous or injectable drugs. These pharmacies are well-equipped to handle such medications. Their role is vital in distributing antifungal and antibiotic treatments. As catheter-related infections rise, hospitals are improving treatment protocols. This will further increase reliance on hospital pharmacies. Their infrastructure and clinical support make them key players in delivering high-quality care for infection management.
By Drug Class
- Cloxacillin
- Echinocandin
- Ceftazidime
- Cefazoline
- Daptomycin
- Others
By Route of Administration
- Oral
- Injectable
By Indication
- Bacterial Infections
- Fungal Infection
- Viral and Parasitic Infections
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Key Players Analysis
Major players in the catheter-related bloodstream infection market are focusing on innovation and strategic growth. These companies are developing advanced antimicrobial and coated catheters to lower infection risks and improve patient care. Key strategies include expanding product portfolios, entering new global markets, and partnering with hospitals. Research and development (R&D) investments are rising to meet changing healthcare demands. Many firms also conduct clinical studies and support awareness programs to promote infection control products and educate healthcare professionals effectively.
One of the leading players is Becton, Dickinson and Company (BD), a global medical technology firm. BD offers advanced catheter solutions designed to reduce the risk of bloodstream infections. The company’s growth strategy includes constant innovation and a strong focus on infection prevention. BD also emphasizes partnerships with healthcare providers to improve patient outcomes. By expanding into emerging markets and supporting education-based initiatives, BD aims to increase market share while promoting patient safety through clinically proven technologies.
- Braun Medical Inc
- Eli Lilly and Company
- GSK plc
- Novartis
- Pfizer Inc.
- Sanofi AG
- SteriMax Inc.
- Teva Pharmaceutical Industries Ltd.
Emerging Trends
1. Focus on Infection-Resistant Catheters
Medical device companies are creating new catheters with infection-resistant coatings. These include antimicrobial and antibiotic materials. The goal is to stop bacteria from sticking to the catheter’s surface. This is important because bacteria buildup is a major cause of bloodstream infections. These improved catheters lower the chance of infection from the start. Hospitals are now more willing to invest in these types of catheters. This trend is expected to continue as demand for safer patient care grows. Patients with long-term catheter use benefit most from this innovation.
2. Increased Adoption of Preventive Protocols
Hospitals are focusing more on preventing infections than just treating them. One big step is training healthcare workers on how to insert and manage catheters properly. Staff are taught to use clean, sterilized tools and follow strict hygiene practices. These simple steps help reduce infection risks. Many hospitals are updating their internal policies to include routine infection checks. This shift toward prevention improves patient outcomes and reduces hospital stays. In the long run, it also helps lower healthcare costs related to treating catheter infections.
3. Rising Use of Central Line Bundles
Healthcare settings are using “central line bundles” more often. These are groups of best practices used during catheter insertion and care. Each step in the bundle is designed to prevent infections. Examples include hand hygiene, using sterile drapes, and daily checks on catheter need. Studies have shown that these bundles lower the risk of catheter-related infections. Hospitals that follow these steps consistently see better results. This trend is growing as more medical centers aim to improve patient safety. Central line bundles are now a key part of infection prevention strategies.
4. Integration of Smart Monitoring Tools
Technology is changing how catheters are managed. Some hospitals now use smart monitoring tools to track catheter use. These systems can alert staff if a catheter has been in place too long. They can also warn of possible infection signs. This helps nurses and doctors act faster to prevent serious issues. These tools also reduce the chance of human error. As healthcare systems focus on efficiency and safety, smart monitoring is becoming more popular. It also helps reduce costs by avoiding unnecessary treatments and hospital readmissions.
5. Shifting Towards Outpatient and Home-Based Care
More patients are receiving catheter-based care outside of hospitals. This includes outpatient clinics and even home care settings. As a result, there is rising demand for safer and easier-to-use catheters. These devices must be simple enough for use by patients or caregivers. They also need features that lower the chance of infection. Manufacturers are now designing catheters specifically for home use. This trend is growing due to rising healthcare costs and patient preference for home recovery. It is also driving innovation in portable and user-friendly catheter solutions.
6. Growing Regulatory Focus on Hospital-Acquired Infections (HAIs)
Governments and health regulators are now taking hospital-acquired infections more seriously. Catheter-related bloodstream infections fall under this category. Hospitals with high infection rates may face fines or funding cuts. This creates strong pressure to improve infection control practices. Many healthcare centers are now investing in better staff training and modern catheter products. Regular audits and reporting are also becoming more common. These regulations are pushing the entire market toward higher safety standards. As a result, infection prevention is now a top priority in healthcare systems around the world.
Use Cases
1. Intensive Care Units (ICUs)
ICU patients often need central venous catheters to receive medication, fluids, or nutrition. These catheters are essential but increase the risk of bloodstream infections. Patients in ICUs are usually critically ill, making infection prevention even more important. The CRBSI market focuses on providing advanced antimicrobial catheters and infection-reducing solutions. Hospitals also use strict protocols and hygiene tools in these units. Specialized coatings, flush systems, and catheter lock solutions are in high demand. These products help lower the risk of infections and improve outcomes. With rising ICU admissions, especially after surgeries or for ventilator support, the market continues to grow in this area.
2. Cancer Treatment Centers
Cancer patients often receive chemotherapy, which weakens the immune system. They usually require frequent IV therapies and long-term catheter use. This makes them highly vulnerable to catheter-related bloodstream infections. To address this, cancer centers are using antimicrobial-coated catheters and infection control tools. These products help reduce risks during treatment. The CRBSI market also offers maintenance kits, disinfectant caps, and easy-to-use dressing changes. These tools help healthcare workers keep catheters clean and safe. As cancer cases rise worldwide, the demand for safer catheter solutions in oncology settings is also increasing steadily.
3. Dialysis Centers
Dialysis patients need repeated catheter access for treatment, especially when permanent fistulas are not an option. These catheters stay in place for long periods, making infection prevention critical. Bloodstream infections are a major concern in dialysis units. The CRBSI market supports these centers with antimicrobial catheters, antiseptic dressings, and catheter lock solutions. These tools help reduce infection rates and improve patient safety. Staff are also trained to follow strict hygiene protocols during insertion and use. As more people require dialysis due to kidney disease, the need for infection-reducing catheter technologies continues to grow.
4. Home Healthcare Services
Some patients use long-term catheters at home, especially those on IV nutrition or antibiotics. These patients often manage their own care or rely on visiting nurses. The risk of infection is high without proper tools and training. The CRBSI market meets this need with home-friendly catheter kits and simplified cleaning supplies. Some kits also include clear instructions and telehealth monitoring devices. This helps patients and caregivers follow correct steps and catch problems early. With the rise of home healthcare and aging populations, demand for infection control products designed for home use is increasing.
5. Emergency and Surgical Departments
Emergency and surgical settings often require quick catheter insertion. In fast-paced environments, there’s a higher risk of introducing bacteria during catheter placement. The CRBSI market provides tools that reduce infection risks, even when time is limited. These include pre-packaged sterile catheter kits, antimicrobial dressings, and quick-disinfectant products. Surgical departments also rely on postoperative infection control tools to prevent CRBSIs after catheter use. As emergency rooms and surgical units continue to manage high patient volumes, the need for fast, reliable infection prevention products remains strong.
6. Pediatric and Neonatal Care
Infants and young children, especially those in neonatal intensive care units (NICUs), often need central lines for nutrition or medication. Their immune systems are still developing, making them more vulnerable to infections. The CRBSI market is developing specialized catheters designed for smaller bodies. These products use gentle materials and antimicrobial coatings for added protection. Hospitals also use pediatric-specific cleaning supplies and securement devices. The focus is on reducing infection risks without harming delicate skin. As neonatal care advances, the demand for safe, child-friendly catheter solutions continues to rise globally.
Conclusion
In conclusion, the catheter-related bloodstream infection market is growing steadily due to rising healthcare awareness and the need for better infection control. Hospitals, clinics, and home care services are all looking for safer and more effective catheter solutions. Innovations like antimicrobial coatings, smart monitoring tools, and home-use kits are helping reduce infection risks. Healthcare providers are focusing more on prevention, training, and better hygiene practices. Support from governments and strong investments in research are also boosting this market. As more patients need long-term catheter care, demand for advanced and safe products will continue to rise. This trend creates strong opportunities for companies developing infection prevention technologies.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
